Roche Just Beat Both Rivals in KRAS Lung Cancer. At the Same Time.

The Trial That Changed the Conversation

Krascendo-1 enrolled 338 patients across multiple countries. It randomized them 1:1 to receive either divarasib (once daily) or their doctor's choice of sotorasib or adagrasib. All patients had KRAS G12C-mutant advanced lung cancer that had already progressed on prior therapy.

This design was audacious. Both comparator drugs are approved, marketed products. Roche essentially told the FDA (and the world): "We're not interested in beating chemo. We want to prove we're better than the current standard."

The gamble paid off. Roche's Chief Medical Officer, Levi Garraway, said the results "should establish divarasib as a new standard of care" for these patients.

One critical caveat: Roche hasn't released the actual numbers yet. No hazard ratios. No median survival figures. No response rates from this trial. Those details will come at a future medical meeting. What we know is the direction (divarasib won) and the statistical rigor (significant on both PFS and OS). The magnitude of the win remains a mystery for now.

What This Means for Amgen and BMS

Let's be blunt: this is bad news for both companies' KRAS franchises.

Amgen's Lumakras has never quite lived up to the hype. Annual global sales sit in the $250-350 million range, respectable but nowhere near blockbuster territory. BMS's Krazati is smaller still, generating roughly $126 million annually. Combined, the KRAS G12C market is probably a $400-600 million pie in 2025.

Now imagine you're an oncologist choosing between three drugs in this class. One just proved in a head-to-head trial that it keeps patients alive longer. The other two were the losing comparators. Which one do you prescribe?

Exactly.

Roche has guided peak divarasib sales of 1-2 billion Swiss francs (roughly $1.2-2.5 billion). That estimate suddenly looks much more credible. Meanwhile, Amgen and BMS face a future where their KRAS drugs get squeezed into a shrinking corner of the market once divarasib launches, likely around 2027.

The Bigger Picture: A New Benchmark for the Class

The competitive implications extend beyond just these three drugs. Several next-generation KRAS inhibitors are in development from companies like Eli Lilly, Jacobio, and Merck. Before Krascendo-1, those programs were benchmarking themselves against sotorasib and adagrasib.

Now the bar has moved. Any future KRAS G12C drug will need to answer a harder question: can you beat divarasib?

Roche isn't stopping at second-line treatment, either. The company is running Krascendo-2, a phase 3 trial combining divarasib with Merck's blockbuster immunotherapy Keytruda in previously untreated advanced or metastatic patients. There's also an adjuvant trial (treating patients right after surgery to prevent recurrence). If those programs succeed, divarasib could expand from a salvage therapy into a drug that touches KRAS G12C patients at every stage of their journey.

What We're Watching

The full dataset will tell us whether this is an incremental improvement or a dramatic leap. A few key questions remain:

How big is the survival benefit? A hazard ratio of 0.7 tells one story. A hazard ratio of 0.5 tells a very different one. The magnitude matters enormously for guideline placement and market adoption.

Does the safety profile hold up? Phase 1 data looked clean, and Roche says no new safety signals emerged. But detailed rates of serious side effects, treatment discontinuations, and quality-of-life data haven't been released yet.

Will regulators grant a superiority label? If the FDA acknowledges head-to-head superiority in the drug's prescribing information, that would be an exceptionally powerful commercial asset.

For now, though, the headline is clear. Roche took the riskiest possible path in clinical development (fight the incumbents directly) and won. In a class that was once considered impossible to drug, the next chapter belongs to Roche.

Denmark's $861M Bet to Become Europe's Biotech Capital

The Novo Nordisk Foundation just made its largest donation ever: $861 million over a decade to turn Denmark's BioInnovation Institute into a European biotech powerhouse. The catch? It's not just about drugs anymore.